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To measure the effects of atopic dermatitis (AD) on the quality of life of affected young children and their families,
we developed a prototype 62-item instrument, the Childhood Atopic Dermatitis Impact Scale (CADIS). The prototype
CADIS was developed from a comprehensive conceptual framework based on data from parents and clinicians. The
instrument had eight subscales (four each for child and parent): physical health, emotional health, physical func-
tioning, and social functioning. The goal of this work was to test the validity of and to reﬁne the prototype of CADIS.
Two hundred seventy parents of children under the age of 6 y with AD responded to the instrument. Content validity
was demonstrated by expert and parent reviews of the drafted and reﬁned instrument, and by analyzing parents’
responses to open-ended questions about their children’s skin disease. Construct validity was assessed in ex-
ploratory factor analyses which supported a reﬁnement in the conceptual framework to consist of two dimensions
with ﬁve domains: child dimensions (symptoms and activity limitation/behavior), and parent dimensions (family/
social function, sleep, and emotions). Seventeen items were eliminated, yielding a 45-item reﬁned version of CADIS
(score 0–180) with evidence of content and construct validity and suggested use in clinical research.
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Atopic dermatitis (AD) is a common pediatric disease, af-
fecting 17% of American children (Laughter et al, 2000) with
dramatic effects on the quality of life of afflicted children
and their parents. AD not only produces physical symptoms
for the child such as pruritus, skin discomfort, and sleep
disruption, but also causes emotional abnormalities and
social dysfunction such as frustration, fussiness, isolation,
negative self-esteem, and poor self-image (Daud et al,
1993; Dahl et al, 1995; Reid and Lewis-Jones 1995; Su et al,
1997; Stores et al, 1998; Reuveni et al, 1999). Parents of
affected children may not only experience sleep distur-
bances, they also report social effects and emotional feel-
ings of guilt, blame, worry, and frustration as a consequence
of their child’s skin disorder (Chamlin et al, 2004).
Several quality-of-life outcome instruments exist for chil-
dren with skin disease (Lewis-Jones and Finlay 1995; Law-
son et al, 1998; Lewis-Jones et al, 2001; McKenna et al,
2005). For AD, the Dermatitis Family Impact (DFI) question-
naire (Lawson et al, 1998), the Infants’ Dermatitis Quality of
Life Index (IDQOL) (Lewis-Jones et al, 2001), and the Par-
ents’ Index of Quality of life in Atopic Dermatitis (PIQoL-AD)
(McKenna et al, 2005) are instruments for which reliability
and validity have been examined. The 10-item DFI and ID-
QOL, which have been useful for clinical research, measure
primarily symptoms and functioning, and assess emotional
effects of AD with a few items. Thus, the extent to which
they comprehensively measure the complex emotional
effects of AD is unknown.
Our previous work (Chamlin et al, 2004) has suggested
that the emotional effects of AD on child and family well-
being are paramount. Based on this research and the pre-
vious work of others (Lewis-Jones and Finlay 1995; Lawson
et al, 1998; Lewis-Jones et al, 2001), we developed a pro-
totype Childhood Atopic Dermatitis Impact Scale (CADIS) to
measure the multidimensional disease- and age-specific
effects of AD on young American children and their parents.
The purpose of this study was to evaluate the validity of and
to refine the prototype version of CADIS.
Results
Sample characteristics Of the 300 enrolled families (52
San Francisco, 248 Chicago), 270 (90%) completed the
prototype CADIS and socio-demographic items. The mean
age of the children was 16.0 months; 55% were male, 52%
were self-identified as Caucasian, and 21% as Asian. The
Abbreviations: AD, atopic dermatitis; CADIS, Childhood Atopic
Dermatitis Impact Scale; EFA, exploratory factor analysis; MnSq,
Rasch Mean Square fit statistics
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mean age of the mothers was 32.8 y; 86% were married or
living with their partner, 81% were privately insured, and
56% reported an income 4$75,000. See Table I.
Reﬁning the prototype CADIS Exploratory factor analysis
(EFA) was conducted on the entire sample, resulting in the
elimination of nine items as follows. For parent-related
items, six significant factors had eigenvalues greater than 1
accounting for 53.89% of the total variance, and three fac-
tors were found before the ‘‘break’’ in the scree-plot. Many
items had significant factor loadings (40.3) on more than
one factor. Moderate correlations among factors (range
0.37–0.69) suggested the possibility of combining factors.
Item 18 was removed for low factor loading, and item 19
was removed as it did not load on any factor. In addition,
item content was reviewed, and four items (21, 29, 31, 60)
were removed that were ambiguous, biased (gender or
treatment), or wordy. Three conceptual domains were iden-
tified from the content review process, and they demon-
strated good internal consistency: family and social function
(11 items), emotions (17 items), and sleep (three items).
These domains were named according to the predominant
construct described. For child-related items, four factors
had eigenvalues greater than 1 accounting for 56.8% of
the total variance, and two factors were identified before the
‘‘break’’ in the scree-plot. Some items significantly loaded
on more than one factor and moderate correlations were
found among factors (range 0.41–0.61). Three items
(3, 4, 22) were removed because of low item-total correla-
tion (o0.4). The rest of the items were grouped into two
domains and named according to the predominant con-
struct described: symptoms (11 items) and activity limita-
tions and behavior (11 items).
Rasch analysis was then used to examine item quality of
each domain, resulting in elimination of three further items.
The sleep domain was not analyzed because of the small
number of items (3). For the domains family and social
function, emotions, and activity limitations and behavior, all
items inquiring about had a Rasch Mean Square fit statistics
(MnSq)o1.4 suggesting these items could be scaled to-
gether. For the symptoms domain, three items (45, 51, 53)
had a high MnSq and were eliminated.
Five further items were removed because many parents
chose the same response. The discriminative capability of
the scales was improved by removing the second item in
each of these pairs of items: 14 and 17, 30 and 36, 15 and
23, 2 and 12, 39 and 55.
Reﬁned conceptual framework Based on the results of
the psychometric analyses and item performance results,
the hypothesized conceptual framework for the effects of
AD on children and their families was modified (Fig 2). We
now hypothesize that the effects of AD on children and their
families can be understood by this five-scale framework.
Internal consistency was acceptable for all hypothesized
scales: family and social function scale, a¼ 0.91 and item-
total correlation range 0.48–0.81; emotion scale, a¼ 0.92
and item-total correlation range 0.42–0.75; sleep scale,
a¼0.76 and item-total correlations range 0.54–0.66; symp-
toms scale, a¼ 0.93, item-total correlation range 0.70–0.84;
activity limitations and behavior scale, a¼0.84, item-total
correlation range 0.39–0.69.
Content validity Two hundred and seventy parents re-
sponded with 453 mentions of the ways that AD bothers
their child and 410 mentions of the ways that AD bothers
them (Tables II and III). Of note, the three most common
mentions for both child bother and parent bother were
itching/scratching, pain/discomfort, and sleep issues. The
content of the responses was compared with the retained
items of the CADIS, and all mentions noted by more than
7% of parents were included.
Discussion
CADIS is a hypothesis-based quality-of-life survey com-
posed after review of published work and based upon
Table I. Characteristics of Children and Parents (n¼ 270)
Variable Frequency n (%)a
Child’s gender
Male 149 (55)
Female 121 (45)
Child’s mean age (mo) 16.0 (SD¼12.7) (range 1.5–71.4)
Child’s race (as identified by parent)
African-American 46 (17)
Caucasian 140 (52)
Asian or Pacific Islander 56 (21)
Hispanic 13 (5)
Other 15 (6)
Parent’s marital status
Single 31 (12)
Married/living with partner 233 (86)
Separated/Divorced 4 (2)
Health insurance
Private insurance 219 (81)
Medicaid 44 (16)
None/Other 7 (3)
Annual family income
Less than $15,000 14 (5)
$15,000–$30,000 30 (11)
$31,000–$45,000 15 (6)
$46,000–$60,000 37 (14)
$61,000–$75,000 20 (7)
More than $75,000 150 (56)
Parent’s mean age (y)
Mother 32.8 (SD¼5.6)
Father 34.9 (SD¼5.9)
aPercentages do not always add up to 100 because of rounding.
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interviews with families and expert medical professionals.
This initial evaluation suggests the validity of the CADIS.
Parent’s emotions are the predominant dimension in a
recently published qualitative investigation of parents with
young children affected by AD (Chamlin et al, 2004), a finding
quantified in this study with 44% of the mentions from par-
ents about what bothers them most about AD pertaining to
emotional effects on the family (Table II). The importance of
this domain in the measurement of the effects of AD is dem-
onstrated by the proportion of related items (17 of 45) that
were retained in the refined CADIS. Previous widely used
measures of quality of life in this patient population (CDLQI,
DFI, IDQOL), which likely underestimate the importance of
this dimension of health, include few items regarding emo-
tional effects of disease (Lewis-Jones and Finlay 1995; Law-
son et al, 1998; Lewis-Jones et al, 2001). These three
instruments have the advantage of brevity and ease in scor-
ing. Although a measurement of the emotional effects of AD
is predominant in the PIQoL-AD, a 28-item instrument
(McKenna et al, 2005), responsiveness may be limited be-
cause of the response choices of ‘‘true’’ or ‘‘not true.’’
Efforts to ensure the content validity of the CADIS include
its basis in the published literature and focused interviews
with parents and expert clinicians (Chamlin et al, 2004). In
addition, expert clinicians and families reviewed the CADIS
before use in this investigation. The same expert group of
clinicians and the study team reviewed the results of the
factor analysis and evaluated the content of the refined
CADIS. Content validity is also demonstrated by inclusion of
most of the common concerns of the parents.
The families enrolled were predominantly Caucasian,
privately insured and married. These demographics may
reflect patients seen in specialty referral-based practices,
and validity of CADIS in all ethnic and social groups cannot
be assumed.
Construct validity was evaluated by testing whether the
relationships between subdimensions in the hypothesized
conceptual framework (Fig 1) were found in responses to
the prototype CADIS. Factor analysis supported a reduced
number of factors. Although these factors corresponded to
domains in our original hypothesis, the revised framework
(Fig 2) with fewer factors and items simplified the concep-
tual framework without compromising the comprehensive
content.
Item reduction was performed by both psychometric
analysis and qualitative judgment to ensure analytic and
clinical legitimacy. The reduction to 45 items decreases the
administration time for the CADIS to approximately 6 min
(compared with 9 min to complete the original version). This
shorter survey will facilitate ease of administration.
These analyses demonstrate evidence of content and
construct validity of the refined version of CADIS as a
measure of the effects of AD on young children and their
parents. This work provides a basis for further test–retest
reliability and responsiveness testing of the 45-item CADIS.
Validity will also be evaluated by comparing the CADIS with
a disease-specific quality-of-life scale and a generic health
status instrument. In addition, the relationship between
CADIS scores (0–180) and disease severity will be evaluat-
ed. After additional evaluation, the CADIS may be utilized in
clinical research.
Table II. Parents’ (n¼ 270) responses to ‘‘What about AD
bothers you the most?
Responses, n¼410 n (%)
Itching/scratching 83 (30.7)
Child’s pain/discomfort 68 (25.2)
Sleep issues 40 (14.8)
Embarrassment or worry about appearancea 30 (11.1)
Child’s fussiness/irritability/crying/unhappiness 21 (7.8)
Helplessness/can’t control it/predict ita 19 (7.0)
Worry: skin infectiona 15 (6.8)
Dryness of skin/non-smooth skin 13 (4.8)
Skin bleeding 12 (4.4)
Worry: damage/scarsa 9 (3.3)
Stares/comments of strangers & other childrena 9 (3.3)
Rashes/redness of skin/discoloration 9 (3.3)
Worry: won’t outgrowa 7 (2.6)
Sadness/feel bada 6 (2.2)
Worry: Long-term effects of meds/side effects steroidsa 6 (2.2)
Bothers child 5 (1.9)
Time to apply meds 5 (1.9)
Worry: fooda 5 (1.9)
Worry: self-esteem/teasing/social acceptancea 5 (1.9)
Child dislikes or burning with med. application 4 (1.5)
Frustration of child 4 (1.5)
‘‘That he/she has it’’a 4 (1.5)
Worry: spread to rest of body/worsena 3 (1.1)
Worry: triggers/exposures/what starts the itcha 3 (1.1)
aMentions categorized as relating to parent emotions, n¼121 (44.4%).
AD, atopic dermatitis.
Table III. Parents’ (n¼ 270) responses to ‘‘What about AD
bothers your child the most?
Responses, n¼453 n (%)
Itch/scratch 229 (84.8)
Burning/irritated skin/discomfort/pain 32 (11.9)
Sleep disruption 27(10)
Bleeding 14 (5.2)
Nothing 13 (4.8)
Dislikes application of medicines 10 (3.7)
Miserable/crying/irritability/fussy 9 (3.3)
Does not like bathing 4 (1.5)
Frustration 3 (1.1)
Self-consciousness/self-esteem 3 (1.1)
AD, atopic dermatitis.
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Materials and Methods
Instrument development A conceptual framework for the effects
of AD on young children and their families was constructed based
on a published work and directed focus sessions with expert cli-
nicians and parents of young children (o6 y of age) with AD (Fig 1)
(Chamlin et al, 2004). Using established principles of psychometric
theory (Nunnally, 1978; Aday, 1989), we composed 62 specific
items to address the dimensions and sub-dimensions of the con-
ceptual framework. An expert group reviewed the drafted pilot in-
strument, which was completed by parents of 20 children with AD.
Items found to be ambiguous were revised, the resulting 62-item
prototype CADIS is contained in the Appendix. CADIS is self-ad-
ministered by the patient’s parent (Eiser and Morse 2001). Stand-
ardized response choices consist of five-category choices relating
to frequency (‘‘never,’’ ‘‘rarely,’’ ‘‘sometimes,’’ ‘‘often,’’ and ‘‘all the
time’’). The CADIS inquires about the parent’s perceptions during
the last 4 wk. Each item is scored from 0 (‘‘never’’) to 4 (‘‘all the
time’’).
Sample population and data collection The parents of three
hundred consecutive young children with AD were approached by
one of the investigators (S. L. C. or A. J. M) and offered partic-
ipation following their child’s scheduled visit. Recruitment took
place at two pediatric dermatology practices (Children’s Memorial
Hospital, Chicago, Illinois and University of California, San Fran-
cisco, San Francisco, California). One family refused to participate.
All parents and primary caregivers provided written informed con-
sent and the study protocol was approved by the Institutional Re-
view Boards at both participating institutions, Children’s Memorial
Hospital and the University of California. The study was conducted
according to Declaration of Helsinki Principles. The sample pop-
ulation consisted of parents or primary caregivers of children from
birth to 6 y of age with a diagnosis of AD and was limited to families
who could read and understand English. Enrolled participants
completed the prototype CADIS, socio-demographic items, and
other clinical questions. Two open-ended questions inquired ‘‘What
about AD bothers your child the most?’’ and ‘‘What about AD
bothers you the most?’’ Parents or caregivers responded to the
CADIS and other measures before leaving the clinic or returned the
completed surveys by mail. Received data were entered using
SPSS data sets.
Analyses To assess construct validity, EFA with principal compo-
nent extraction and varimax rotation was used to identify the factor
structure underlying the 62-item CADIS. Parent- and child-related
items were analyzed separately. The number of reliable factors was
determined by examining the magnitude of the eigenvalues and the
associated scree-plot. Eigenvalues greater than 1 and the plots
were used to identify a break between factors explaining relatively
large and small amounts of variance. Factor loadings (the regres-
sion coefficients of items on each factor) were examined to de-
termine the strength of the relationship between each item and
factor. Items with factor loadings equaling or greater than 0.3 were
retained for further analysis.
The performance of individual items was assessed in several
ways. Item-total correlations were evaluated for each item and
Cronbach’s coefficient a was calculated for each factor determined
by the EFA. MnSq implemented in WINSTEPS (Linacre, 2003) were
used to examine the response pattern of the items. Items with low
item total correlation (o0.4), and items with MnSq41.4 (suggesting
that more than 40% of random variance (noise) was identified on the
Figure 1
Original conceptual framework for the effects of skin disease on quality of life. This hypothesis was based on a literature review and directed
focus sessions with experts and parents. The constructs addressed by the eight scales of Childhood Atopic Dermatitis Impact Scale are bordered
with double lines.
Figure 2
Revised framework for the effects of skin disease on quality of life. Factor analysis supported the five constructs bordered in double lines.
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item) were considered for elimination. The content of each item was
re-reviewed and items that appeared redundant in content and for
which many parents chose the same response were considered to
have poor discriminative capability and were considered for elim-
ination. Final decision about elimination of items was based on re-
view of all psychometric data on item performance.
To assess content validity, all responses to the two open-ended
questions were recorded, categorized and compared with items in
the refined CADIS.
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Appendix: 62-item prototype CADIS Italicized items were
removed to generate the 45-item CADIS. Constructs cor-
responding to the framework in Fig 1 are represented as
follows: Child physical health (CPH), child physical func-
tioning (CPF), child social functioning (CSF), child emotional
health (CEH), parent physical health (PPH), parent physical
functioning (PPF), parent social functioning (PSF), parent
emotional health (PEH).
1. This skin condition affects how well my child sleeps.
(CPH)
2. Because of this skin condition, I limit my child’s outdoor
activities such as playing at parks or beaches. (CPF)
3. Relatives and friends avoid holding or touching my child
because of this skin condition. (CSF)
4. I restrict my child from eating foods that he or she wants
because of this skin condition. (CEH)
5. My child’s skin condition affects how well my spouse
and I sleep. (PPH)
6. I am bothered that this skin condition affects our va-
cation plans. (PPF)
7. This skin condition affects our social life. (PSF)
8. This skin condition makes my child fussy or irritable.
(CEH)
9. I am bothered that my family stays home more because
of this skin condition. (PPF)
10. I am bothered that this skin condition affects our rela-
tionships with relatives. (PSF)
11. My child scratches or rubs his/her skin. (CPH)
12. I limit my child’s swimming because of this skin condi-
tion. (CPF)
13. This skin condition makes my child feel frustrated.
(CEH)
14. I worry about leaving my child with others (babysitters,
relatives) because of this skin condition. (PPF)
15. My child seems to cry more because of this skin con-
dition. (CEH)
16. I worry that my child’s skin condition will continue. (PEH)
17. This skin condition has affected my child care arrange-
ments. (PPF)
18. My child’s skin condition affects the happiness of my
other children. (PSF)
19. I am angry at my child for scratching his/her skin. (PEH)
20. My child’s skin seems to be painful or irritated. (CPH)
21. I worry about whether my child will outgrow this skin
condition. (PEH)
22. I limit my child’s baths because of this skin condition.
(CPF)
23. My child may want to be held more because of this skin
condition. (CEH)
24. I am frustrated with my child’s skin condition. (PEH)
25. I/we avoid taking photos of my child because of this
skin condition. (PPF)
26. My child seems to be restless or hyperactive because
of this skin condition. (CEH)
27. I am bothered by how much time is needed to care for
my child’s skin condition. (PPF)
28. I worry about the costs of my child’s skin condition.
(PEH)
29. I am tired because of my child’s skin condition. (PPH)
30. My child’s skin condition affects my spouse’s or my
work performance due to missed time and decreased
productivity. (PPF)
31. I blame myself or feel guilty that my child’s skin condition
still persists despite treatment. (PEH)
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32. Taking a bath makes my child uncomfortable. (CPH)
33. My child’s itching or scratching affects his/her play.
(CPF)
34. I feel helpless about my child’s skin condition. (PEH)
35. My child scratches his/her skin to get attention. (CEH)
36. My child’s skin condition has affected my spouse’s or my
decision to work outside the home. (PPF)
37. I am bothered by the reaction of strangers to this skin
condition. (PSF)
38. I am disappointed that my child has this skin condition.
(PEH)
39. Certain fabrics or clothes seem to bother my child’s
skin. (CPH)
40. I worry that my child is exposed to things that may
worsen this skin condition. (PEH)
41. It is difficult to discipline my child because of this skin
condition. (CEH)
42. My child’s skin condition has strained my relationship
with my spouse or partner. (PEH)
43. My child sleeps in my bed because of this skin con-
dition. (PPF)
44. I worry about the side effects from treatments for this
skin condition. (PEH)
45. I hold or cover my child’s hands to prevent him/her from
scratching. (CPF)
46. I worry that this skin condition will affect my child’s
ability to make friends. (PEH)
47. My child misbehaves more because of this skin con-
dition. (CEH)
48. This skin condition has affected how confident I feel
about my child’s medical care. (PEH)
49. I am bothered by my child sleeping in my bed. (PPF)
50. I am angry that my child has this skin condition.
(PEH)
51. Getting my child to take oral medicines for this skin
condition is difﬁcult. (CEH)
52. I worry that this skin condition will affect my child’s self-
esteem. (PEH)
53. My child’s skin bleeds because of this skin condition.
(CPH)
54. My child’s skin condition makes me feel sad or de-
pressed. (PEH)
55. I restrict my child’s contact with pets because of this skin
condition. (CPF)
56. My child’s skin condition has affected my decision to
have other children. (PEH)
57. Children seem to avoid touching or playing with my
child because of this skin condition. (CSF)
58. I blame myself or feel guilty that my child has this skin
condition. (PEH)
59. My child dislikes having creams and ointments applied
to his or her skin. (CEH)
60. I am bothered that I have more housework or laundry
because of this skin condition. (PPF)
61. I am embarrassed by the way my child’s skin looks.
(PEH)
62. My child’s skin condition makes it hard to do what I
enjoy. (PSF)
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